Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
CLA3884 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00006 | 35256934 | Acta Pharm Sin B | Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. | 2021 | Details |
| A00023 | 35251371 | Dis Markers | Dose-Response Associations of Metabolic Score for Insulin Resistance Index with Nonalcoholic Fatty Liver Disease among a Nonobese Chinese Population: Retrospective Evidence from a Population-Based Cohort Study. | 2022 | Details |
| A00029 | 35250856 | Front Endocrinol (Lausanne) | Not Enough Fat: Mouse Models of Inherited Lipodystrophy. | 2022 | Details |
| A00034 | 35249505 | Curr Drug Saf | Pioglitazone, Bladder Cancer and the Presumption of Innocence. | 2022 | Details |
| A00035 | 35249343 | Ann Palliat Med | Serum level of free thyroxine is an independent risk factor for non-alcoholic fatty liver disease in euthyroid people. | 2022 | Details |
| A00065 | 35233386 | J Clin Transl Hepatol | Influence of Nonalcoholic Fatty Liver Disease on the Occurrence and Severity of Chronic Kidney Disease. | 2021 | Details |
| A00078 | 35229183 | Pediatr Radiol | Diagnostic performance of ultrasound hepatorenal index for the diagnosis of hepatic steatosis in children. | 2022 | Details |
| A00088 | 35223941 | Front Nutr | Cumulative Betel Quid Chewing and the Risk of Significant Liver Fibrosis in Subjects With and Without Metabolic Syndrome. | 2022 | Details |
| A00101 | 35219732 | Eur J Pharmacol | mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis. | 2022 | Details |
| A00111 | 35216753 | Lancet Digit Health | Development and validation of an ensemble machine learning framework for detection of all-cause advanced hepatic fibrosis: a retrospective cohort study. | 2022 | Details |
| A00121 | 35213002 | Methods Mol Biol | Analysis of the Sphingolipidome in NAFLD. | 2022 | Details |
| A00155 | 35206988 | Healthcare (Basel) | Effects of Different Scan Projections on the Quantitative Ultrasound-Based Evaluation of Hepatic Steatosis. | 2022 | Details |
| A00157 | 35204710 | Biomolecules | Posttranscriptional Regulation of Insulin Resistance: Implications for Metabolic Diseases. | 2022 | Details |
| A00158 | 35204522 | Diagnostics (Basel) | A Comparative Study of the Triglycerides/HDL Ratio and Pseudocholinesterase Levels in Patients with Bladder Cancer. | 2022 | Details |
| A00163 | 35203662 | Biomedicines | The Concept of Indeterminable NASH Inducted by Preoperative Diet and Metabolic Surgery: Analyses of Histopathological and Clinical Features. | 2022 | Details |
| A00180 | 35196341 | PLoS One | The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy. | 2022 | Details |
| A00208 | 35185803 | Front Endocrinol (Lausanne) | Single Point Insulin Sensitivity Estimator in Pediatric Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A00218 | 35180651 | Pathol Res Pract | Stage-dependent expression of fibrogenic markers in alcohol-related liver disease. | 2022 | Details |
| A00220 | 35178663 | Hepatol Int | Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank. | 2022 | Details |
| A00247 | 35167194 | J Diabetes Investig | Fatty liver with metabolic disorder, such as metabolic dysfunction-associated fatty liver disease, indicates high risk for developing diabetes mellitus. | 2022 | Details |
| A00255 | 35163991 | Molecules | Sitagliptin Is More Effective Than Gliclazide in Preventing Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A00257 | 35163821 | Int J Mol Sci | Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome. | 2022 | Details |
| A00272 | 35158328 | J Physiol Pharmacol | Current approach to hepatobiliary manifestations in inflammatory bowel disease. | 2022 | Details |
| A00279 | 35154005 | Front Endocrinol (Lausanne) | Novel Subgroups and Chronic Complications of Diabetes in Middle-Aged and Elderly Chinese:A Prospective Cohort Study. | 2022 | Details |
| A00295 | 35147926 | J Endocrinol Invest | Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. | 2022 | Details |
| A00298 | 35146945 | Hepatol Commun | A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00300 | 35145074 | Nat Commun | Small molecule SWELL1 complex induction improves glycemic control and nonalcoholic fatty liver disease in murine Type 2 diabetes. | 2022 | Details |
| A00301 | 35144542 | BMC Gastroenterol | Contribution of classification based on ferroptosis-related genes to the heterogeneity of MAFLD. | 2022 | Details |
| A00326 | 35134438 | Life Sci | Fluorene-9-bisphenol exposure decreases locomotor activity and induces lipid-metabolism disorders by impairing fatty acid oxidation in zebrafish. | 2022 | Details |
| A00337 | 35129841 | Hepatol Res | The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease. | 2022 | Details |
| A00343 | 35127371 | Acta Pharm Sin B | Therapeutic regulation of autophagy in hepatic metabolism. | 2021 | Details |
| A00363 | 35119232 | J Basic Clin Physiol Pharmacol | Is it possible to treat nonalcoholic liver disease using a flavanol-based nutraceutical approach? Basic and clinical data. | 2022 | Details |
| A00366 | 35116505 | Transl Cancer Res | Low expression of AQP9 and its value in hepatocellular carcinoma. | 2021 | Details |
| A00368 | 35115798 | Diabetes Metab Syndr Obes | Association of Circulating TXNIP Levels with Fatty Liver in Newly Diagnosed Type 2 Diabetes Mellitus. | 2022 | Details |
| A00415 | 35093101 | J Transl Med | Single-cell transcriptomic analysis reveals a novel cell state and switching genes during hepatic stellate cell activation in vitro. | 2022 | Details |
| A00416 | 35092912 | EBioMedicine | The influence of host genetics on liver microbiome composition in patients with NAFLD. | 2022 | Details |
| A00422 | 35090960 | J Hepatol | Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. | 2022 | Details |
| A00435 | 35085294 | PLoS One | Quantitative ultrasound, elastography, and machine learning for assessment of steatosis, inflammation, and fibrosis in chronic liver disease. | 2022 | Details |
| A00451 | 35077243 | J Cardiovasc Pharmacol Ther | The Association of Alanine Aminotransferase Levels With Myocardial Perfusion Imaging and Cardiovascular Morbidity. | 2022 | Details |
| A00466 | 35070015 | World J Hepatol | Determination of "indeterminate score" measurements in lean nonalcoholic fatty liver disease patients from western Saudi Arabia. | 2021 | Details |
| A00489 | 35064417 | Qual Life Res | The effect of polypharmacy on quality of life in adult patients with nonalcoholic fatty liver disease in the United States. | 2022 | Details |
| A00495 | 35061826 | PLoS One | A nationwide survey of the association between nonalcoholic fatty liver disease and the incidence of asthma in Korean adults. | 2022 | Details |
| A00504 | 35058782 | Front Pharmacol | TMEM88 Modulates Lipid Synthesis and Metabolism Cytokine by Regulating Wnt/β-Catenin Signaling Pathway in Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A00508 | 35058147 | Eur J Intern Med | Derivation and validation of the NAFLD Cirrhosis Score (NCS) to distinguish bridging fibrosis from cirrhosis. | 2022 | Details |
| A00515 | 35055177 | Int J Mol Sci | Inulin Improves Diet-Induced Hepatic Steatosis and Increases Intestinal Akkermansia Genus Level. | 2022 | Details |
| A00526 | 35053205 | Biomolecules | Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. | 2021 | Details |
| A00529 | 35052872 | Biomedicines | Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update. | 2022 | Details |
| A00531 | 35052840 | Biomedicines | From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights. | 2022 | Details |
| A00546 | 35051605 | J Ethnopharmacol | Xiaoyao Powder in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2022 | Details |
| A00567 | 35045632 | Zhonghua Gan Zang Bing Za Zhi | [Study on plasma Golgi protein 73 and related models in the diagnosis of nonalcoholic fatty liver disease]. | 2021 | Details |
| A00582 | 35040495 | Eur J Clin Invest | Assessment of clinically significant portal hypertension by two-dimensional shear wave elastography. | 2022 | Details |
| A00595 | 35035496 | Evid Based Complement Alternat Med | Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPARα Signaling Pathway. | 2022 | Details |
| A00605 | 35032633 | Clin Gastroenterol Hepatol | Spleen Size Does Not Correlate With Histological Stage of Liver Disease in People With Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00609 | 35030323 | Lancet Gastroenterol Hepatol | Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. | 2022 | Details |
| A00624 | 35024184 | J Adv Res | Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism. | 2021 | Details |
| A00632 | 35021598 | Clin Mol Hepatol | Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study. | 2022 | Details |
| A00648 | 35015002 | Food Funct | Higher serum vitamin A is associated with a worsened progression of non-alcoholic fatty liver disease in adults: a prospective study. | 2022 | Details |
| A00663 | 35010976 | Nutrients | Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota. | 2021 | Details |
| A00666 | 35010924 | Nutrients | Lactoferrin Prevents Hepatic Injury and Fibrosis via the Inhibition of NF-κB Signaling in a Rat Non-Alcoholic Steatohepatitis Model. | 2021 | Details |
| A00674 | 35007392 | Liver Int | Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link? | 2022 | Details |
| A00675 | 35006629 | Hepatology | Progressive loss of hepatocyte nuclear factor 4 alpha activity in chronic liver diseases in humans. | 2022 | Details |
| A00676 | 35005800 | Aliment Pharmacol Ther | A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease. | 2022 | Details |
| A00679 | 35005107 | Genes Dis | Critical roles of FTO-mediated mRNA m6A demethylation in regulating adipogenesis and lipid metabolism: Implications in lipid metabolic disorders. | 2021 | Details |
| A00687 | 35003513 | Oxid Med Cell Longev | TNF-Like Ligand 1 Aberrance Aggravates Nonalcoholic Steatohepatitis via M1 Macrophage Polarization. | 2021 | Details |
| A00694 | 35000203 | Hepatology | Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD. | 2022 | Details |
| A00695 | 35000120 | Clin J Gastroenterol | The impact of emricasan on chronic liver diseases: current data. | 2022 | Details |
| A00702 | 34997649 | J Clin Lab Anal | The association between non-alcoholic fatty liver disease and serum ferritin levels in American adults. | 2022 | Details |
| A00730 | 34986375 | J Affect Disord | Association between nonalcoholic fatty liver disease and depression: A systematic review and meta-analysis of observational studies. | 2022 | Details |
| A00765 | 34975333 | Int J Biol Sci | Implication of the hepatokine, fibrinogen-like protein 1 in liver diseases, metabolic disorders and cancer: The need to harness its full potential. | 2022 | Details |
| A00785 | 34966656 | J Clin Transl Hepatol | Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille? | 2021 | Details |
| A00819 | 34957487 | Diabetes | Active Brown Adipose Tissue is Associated With a Healthier Metabolic Phenotype in Obesity. | 2021 | Details |
| A00830 | 34954945 | Zhonghua Wai Ke Za Zhi | [Clinical effect of minimally invasive duodenum preserving pancreatic head resection for benign and pre-malignant lesions of pancreatic head]. | 2022 | Details |
| A00835 | 34953171 | J Magn Reson Imaging | The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis. | 2021 | Details |
| A00839 | 34951726 | Hepatology | Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease. | 2022 | Details |
| A00854 | 34945677 | Foods | Lactobacillus plantarum MA2 Ameliorates Methionine and Choline-Deficient Diet Induced Non-Alcoholic Fatty Liver Disease in Rats by Improving the Intestinal Microecology and Mucosal Barrier. | 2021 | Details |
| A00870 | 34944452 | Biomolecules | Digital Pathology Enables Automated and Quantitative Assessment of Inflammatory Activity in Patients with Chronic Liver Disease. | 2021 | Details |
| A00896 | 34938193 | Front Pharmacol | Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. | 2021 | Details |
| A00903 | 34933963 | Open Heart | Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis. | 2021 | Details |
| A00908 | 34933425 | Zhonghua Gan Zang Bing Za Zhi | [Intestinal flora polymorphisms with different lesional stages in an animal model of MAFLD]. | 2021 | Details |
| A00909 | 34933319 | Ultrasonography | Assessment of the inter-platform reproducibility of ultrasound attenuation examination in nonalcoholic fatty liver disease. | 2021 | Details |
| A00922 | 34928469 | Adv Ther | Changes in Platelet Counts and Thrombocytopenia Risk in Patients with Chronic Liver Disease with Different Etiologies Using Real-World Japanese Data. | 2021 | Details |
| A00923 | 34928415 | Eur Radiol | MR elastography in nonalcoholic fatty liver disease: inter-center and inter-analysis-method measurement reproducibility and accuracy at 3T. | 2021 | Details |
| A00925 | 34927450 | J Am Heart Assoc | Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort. | 2021 | Details |
| A00972 | 34915036 | Metabolism | Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers. | 2021 | Details |
| A00992 | 34907906 | J Clin Invest | Dietary sugar restriction reduces hepatic de novo lipogenesis in boys with fatty liver disease. | 2021 | Details |
| A01008 | 34904038 | World J Hepatol | Abnormal liver enzymes: A review for clinicians. | 2021 | Details |
| A01009 | 34904031 | World J Hepatol | Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. | 2021 | Details |
| A01019 | 34901909 | Lancet Reg Health Eur | Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). | 2021 | Details |
| A01025 | 34899679 | Front Immunol | Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. | 2021 | Details |
| A01030 | 34896638 | Ann Hepatol | Laparoscopic cholecystectomy: Histopathological analysis of metabolic associated fatty liver disease and fibrosis. | 2021 | Details |
| A01050 | 34887931 | Evid Based Complement Alternat Med | Pharmacodynamic Evaluation of the Gexia Zhuyu Decoction in the Treatment of NAFLD and the Molecular Mechanism Underlying the TRPM4 Pathway Regulation. | 2021 | Details |
| A01065 | 34882949 | Diabetes Obes Metab | Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database. | 2022 | Details |
| A01105 | 34868307 | Gastroenterol Res Pract | Is the Occurrence or Reversal of Nonalcoholic Fatty Liver Disease Associated with Long-Term Helicobacter pylori Infection among Chinese Adults? A Cohort Study. | 2021 | Details |
| A01126 | 34862596 | Br J Pharmacol | Ruthenium 360 and mitoxantrone inhibit mitochondrial calcium uniporter channel to prevent liver steatosis induced by high-fat diet. | 2022 | Details |
| A01135 | 34859497 | J Gastroenterol Hepatol | Low serum pancreatic amylase levels as a novel latent risk factor for colorectal adenoma in non-alcohol drinkers. | 2021 | Details |
| A01136 | 34859106 | J Immunol Res | Hyperlipidemia May Synergize with Hypomethylation in Establishing Trained Immunity and Promoting Inflammation in NASH and NAFLD. | 2021 | Details |
| A01148 | 34854929 | Eur Radiol | Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease. | 2021 | Details |
| A01182 | 34836382 | Nutrients | The Interplay of Vitamin D Deficiency and Cellular Senescence in The Pathogenesis of Obesity-Related Co-Morbidities. | 2021 | Details |
| A01189 | 34835937 | Nutrients | Reduced Rank Regression-Derived Dietary Patterns Related to the Fatty Liver Index and Associations with Type 2 Diabetes Mellitus among Ghanaian Populations under Transition: The RODAM Study. | 2021 | Details |
| A01193 | 34831479 | Cells | Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. | 2021 | Details |